Mad Money

Cramer Remix: Here's the problem with Apple

Cramer: Here's the problem with Apple

Jim Cramer saw investors try to hide from China on Tuesday. They certainly tried their best and then cringed with pain when they were whacked upside the head by the plunging averages, yet again.

Unfortunately, for some stocks, there is no escaping China.

Even Apple couldn't hide from China when it dropped more than 3 percent on Tuesday. It recently reported a quarter where it sold 3 million fewer phones than analysts expected. Cramer saw that almost immediately following earnings, a broad consensus developed that assumed the iPhone miss was almost entirely due to the Chinese market.

"So, every time we get bad news out of China, like the doom and gloom from BMW last night, it reminds us that if Apple's most recent quarter had included July in the numbers, it would have been far worse," Cramer said.

And Cramer totally understands this logic as Apple's Chinese business now represents 26.7 percent of its sales, up about 15 percent from one year ago. And even though CEO Tim Cook assured investors that sales were strong in China this quarter, Cramer wonders if that is short-lived, based on how much the Chinese government is propping up its market.

So, while Cramer doesn't know how weak or strong Chinese sales really are, he does know one thing—Apple's stock has a really ugly chart.

"It's a fact of life. The stock is not for the squeamish, and it's both over-owned and over-loved," Cramer said. (Tweet This)

Meaning, Cramer thinks that too many analysts are recommending it and too many institutions are over-weighted in it and feel trapped.

However, he continues his long-term view with Apple, and accepts that there might be some Chinese weakness reflected in the share price. Thus, he continues to hold Apple in his charitable trust and is looking to buy more, not sell.

Read More Cramer: Why Apple is not for the squeamish

Customers pose for a photograph inside Apple Inc.'s new Canton Road store in the Tsim Sha Tsui district of Hong Kong, China, on Thursday, July 30, 2015.
Xaume Olleros | Bloomberg | Getty Images

Another stock that was slammed on Tuesday was Brunswick Corporation, the world's top maker of recreational boats, boat engines, billiard tables and fitness machines. Cramer basically considers it the ultimate discretionary spending play.

Brunswick delivered a strong quarter last week, yet the stock was still trading below when it reported. Could this be a terrific entry point for Brunswick, or is it rough seas ahead?

To find out, Cramer spoke with Brunswick Chairman and CEO Dusty McCoy.

"We are tickled to death at the quarter. We were up 11 percent on a constant currency basis. If you look at our stock performance year after year, every year when we report second-quarter earnings we go down a little. We report third-quarter earnings, and we start coming back," McCoy said.

Believe it or not, sometimes even Cramer doesn't have the answer when fans ask him about certain stocks. When that occurs, he considers it his duty to do his homework and provide an opinion on the stocks that stumped him.

On July 15 a caller asked about UniQure. This is a gene therapy developer that is working to create therapies to cure serious disorders in one shot. Its lead drug was approved in Europe for a subset of patients with LPLD, a rare genetic disease that can lead to multiple attacks of pancreatitis.

Additionally, UniQure has a pipeline with earlier-stage programs with therapies for hemophilia and congestive heart failure. It also entered into a partnership with Bristol-Myers back in April to work together on cardiovascular therapies. In Cramer's research he thinks that gene therapies have the potential to be huge.

"That makes me think UniQure's worth speculating on. Seems like a good one to me," the "Mad Money" host said.

So while the "Mad Money" host tries his best to know most stocks, sometimes he has to crunch the research and get to know stocks before providing an opinion. In this case he is willing to recommend UniQure, Karyopharm and Array.

Read More Cramer: Rare biotechs that stumped me

Baxter International Inc.
Brent Lewin | Bloomberg | Getty Images

What the heck happened to Halyard Health? It was seriously creamed on Tuesday when it tanked 11 percent. Halyard is the medical supply company that was spun off by Kimberly-Clark last year, and makes surgical and infection prevention products for the operating room along with a number of other medical supplies.

On Tuesday it reported earnings of a 1-cent miss from a 53-cent basis, with weaker than anticipated revenues that shrank 6 percent, year over year. Additionally its surgical- and infection-prevention business was down 11 percent, even though its medical-device division posted 5 percent growth.

It was certainly a tough quarter, but did Halyard deserve the beating it received in a single session? To find out more, Cramer spoke with Halyard Health's chairman and CEO, Robert Abernathy.

"The problem we had this quarter was in our surgical- and infection-prevention products. We saw some price loss, we saw some market share loss and we are focused on turning that around in the short term. But we are squarely on task in terms of delivering the long-term strategic shift towards medical devices," Abernathy said.

Cramer has always said that sometimes the easiest way for a company to create value is to split itself up into understandable parts for investors.

The "Mad Money" host has been a huge fan of the school of thought that breaking up is easy to do. The question is how they choose to do it. Management in some companies choose to shed their poorly performing divisions, while others choose to unlock value by splitting up into a multi-division company.

On Tuesday, Cramer heard terrific news of two top companies choosing to split up to bring out more value—Baxter International and RR Donnelley. Cramer has been pushing for Baxter to split up for ages, and even dedicated a chapter to it in his book "Get Rich Carefully." He pushed for it to broken up into a slower growing, methodical device company, and a fast ramping biosciences company.

"I salute both management teams for recognizing the need to create easy to understand structures that immediately unlock value," Cramer added.

Ultimately, Cramer wants other management teams to realize that breaking up doesn't always have to be hard to do. It can be both easy and lucrative in the long run.

Read More Cramer: Most lucrative way to unlock stock value

In the Lightning Round, Cramer gave his take on a few caller-favorite stocks:

Nutrisystem Inc: "The stock has had a very, very big run. I feel that we are a little bit late on this one. I congratulate those guys for looking like they're doing pretty good. I would say that I like Under Armour on a pullback because I like that fitness connection business he's got. Wow!"

LinkedIn Corp: "I've got to tell you, I'm getting tired of LinkedIn reporting a quarter that I can't understand and I could not understand this one. They have got to really simplify their financials. I'm going to have to say to take a pass on LinkedIn, or sell it."

Read MoreLightning Round: What the heck do the financials say?